Name: 4D-150 in Neovascular age-related macular degeneration: Dosage forms and strengths
Published: 2026-09-17T18:33:01-04:00

Product information and disease description Product description Product information

Dosage forms and strengths

3 evidence topics · 3 sources

Phase 3 dose and route

“Experimental: 4D-150 IVT (3E10 vg/eye) Biological: 4D-150 IVT (3E10 vg/eye) If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1” (opens the source at this quote in a new tab)

Doses studied in clinical trials

“PRISM enrolled patients with severe, recalcitrant disease with high anti-VEGF treatment burden (Phase 1/2a, 25 patients dosed with Phase 3 dose of 3E10 vg/eye) and with broad disease activity and treatment burden (Phase 2b, 30 patients dosed with Phase 3 dose).” (opens the source at this quote in a new tab)
“In total, 71 patients have been dosed with the Phase 3 dose of 3E10 vg/eye.” (opens the source at this quote in a new tab)

“Synthetic R100 capsid optimized for IVT; Dose: 6 × 10⁹ –3 × 10¹⁰ vg/eye” (opens the source at this quote in a new tab)

Dose levels evaluated in the diabetic macular edema trial

“In the Dose Confirmation cohort, patients were sequentially enrolled to one of three dose arms of 4D-150 (5E9, 1E10 and 3E10 vg/eye).” (opens the source at this quote in a new tab)

Commercial formulation, container, and storage conditions

No evidence found.